Abstract:Background: Clear cell renal cell carcinoma (ccRCC) is one of the most common urological malignancies, and once metastasis occurs, it often has a poor prognosis and lacks effective treatment. Therefore, there is an urgent need to screen some new biomarkers and explore their molecular mechanisms to improve the early clinical diagnosis and targeted therapy of ccRCC. SPOCK1 (SPARC/osteonectin, CWCV and Kazal-like domains proteoglycan 1) is a conserved multi-domain proteoglycan that plays an important role in the development of multiple cancer types; however, its prognostic value in ccRCC has not been investigated. The study of the prognostic value of SPOCK1 in ccRCC is a good complement to the study of ccRCC biomarkers. Methods: Databases of this study included Oncomine, Kaplan-Meier Plotter, GEPIA, GeneMANIA, cBioPortal, and TIMER. Student's t-test was used to analyze the differences in SPOCK1 expression in ccRCC tissues compared with tumor-adjacent normal tissues. Kaplan-Meier curves for survival analysis were used to assess the correlation between the expression of SPOCK1 and the prognostic outcomes. Correlation module drew the expression scatterplots between SPOCK1 and immune cell infiltration in ccRCC, together with the Spearman's rho value and estimated statistical significance. Results: The SPOCK1 mRNA expression was significantly higher in ccRCC tissues (mean expression ± SD: 920.2±195.2) than in normal tissues (mean expression ± SD: 358.4±29.1, P=0.008), and high SPOCK1 expression significantly and positively correlated with the pathological stage of ccRCC patients (F value =10.2, P<0.001). Higher expression of SPOCK1 was also associated with significantly shorter overall survival (OS) and disease-free survival (DFS) in ccRCC patients (GEPIA: P=0.046, P<0.001, respectively; Kaplan-Meier Plotter: P=0.002, P=0.0022, respectively). The function of SPOCK1 is mainly related to tumor development and extracellular matrix remodeling, and it may participate in the epithelial-mesenchymal transition process. SPOCK1 expression significantly and positively correlated with infiltration of several immune cells in ccRCC, including cancer-associated fibroblasts (CAFs) (Rho =0.333, P=2.16×10-13), tumor-associated macrophages (TAMs) (Rho =0.18, P=1.02×10-4), and tumor-associated neutrophils (TANs) (Rho =0.165, P=3.83×10-4). Conversely, there was a significant and negative correlation between SPOCK1 expression and infiltration of CD4+ T cells (Rho =-0.113, P=0.015). Conclusions: SPOCK1 may be a potential prognostic biomarker in ccRCC.

Spock1/Six1axis Promotes Breast Cancer Progression By Activating Akt/Mtor Signaling

SPOCK1 promotes breast cancer progression via interacting with SIX1 and activating AKT/mTOR signaling pathway

SPOCK1 As a Potential Cancer Prognostic Marker Promotes the Proliferation and Metastasis of Gallbladder Cancer Cells by Activating the PI3K/AKT Pathway

SPOCK1 promotes metastasis in pancreatic cancer via NF-κB-dependent epithelial-mesenchymal transition by interacting with IκB-α

SPOCK1 Promotes Tumor Growth and Metastasis in Human Prostate Cancer

SPOCK1 Promotes the Proliferation, Migration and Invasion of Glioma Cells Through PI3K/AKT and Wnt/β-catenin Signaling Pathways.

SPOCK1 is a novel transforming growth factor-β target gene that regulates lung cancer cell epithelial-mesenchymal transition.

SPOCK: Master regulator of malignant tumors (Review)

SPOCK1 is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice

Multiomic Analysis of the Function of SPOCK1 Across Cancers: an Integrated Bioinformatics Approach

Abstract 5309: Characterization of a Novel Oncogene SPOCK1 in Humanhepatocellular Carcinoma.

SPOCK1 Overexpression Suggests Poor Prognosis of Ovarian Cancer

SPOCK1 is a Prognostic-Related Biomarker and Correlated with Immune Infiltrates in Head and Neck Squamous Cell Carcinoma

Knockdown of SPOCK1 Inhibits the Proliferation and Invasion in Colorectal Cancer Cells by Suppressing the PI3K/Akt Pathway

SIX1 Amplification Modulates Stemness and Tumorigenesis in Breast Cancer.

Assessment of the prognostic value of SPOCK1 in clear cell renal cell carcinoma: a bioinformatics analysis

SIX1 Predicts Poor Prognosis and Facilitates the Progression of Non-small Lung Cancer via Activating the Notch Signaling Pathway

The novel prognostic marker SPOCK2 regulates tumour progression in melanoma

SPOCK2 Affects the Biological Behavior of Endometrial Cancer Cells by Regulation of MT1-MMP and MMP2

Sineoculis Homeobox Homolog 1 Protein is Associated with Breast Cancer Progression and Survival Outcome

SPOCK1 contributes to the third-generation EGFR tyrosine kinase inhibitors resistance in lung cancer.